<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045431</url>
  </required_header>
  <id_info>
    <org_study_id>CON-OA-001</org_study_id>
    <nct_id>NCT04045431</nct_id>
  </id_info>
  <brief_title>Treatment of Knee Osteoarthritis With PAAG-OA</brief_title>
  <acronym>ROSA</acronym>
  <official_title>A Multi-centre Randomized, Controlled, Double-blind Clinical Investigation of Intra-articular Polyacrylamide Hydrogel in Subjects With Knee Osteoarthritis Followed by an Open Label Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contura</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Contura</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind clinical investigation to compare the&#xD;
      effectiveness of intra-articular polyacrylamide hydrogel (PAAG-OA) and a hyaluronic acid,&#xD;
      Synvisc-One to induce symptomatic benefit in subjects with knee osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2026</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The subject and study staff will not know the treatment received. Only the unblinded injector will know the treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Comparing one injection of PAAG-OA with one injection of Synvisc-One on pain over 6 months in subjects with knee osteoarthritis</measure>
    <time_frame>6 months</time_frame>
    <description>Change in WOMAC (WOMAC Osteoarthritis Index) pain subscale. Pain is reported in each of five response categories (0=none, 4=extreme)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>WOMAC (WOMAC Osteoarthritis Index) self reported pain, stiffness and physical function, categories (0=none, 4=extreme)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA (Patient Global Assessment)</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>PGA reported on a 10 cm Visual Analogue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L, QoL</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>EQ-5D-5L, Quality of Life, comprised of descriptive system where each dimension has 5 levels (ranging from no problems to extreme problems) and a 20 cm Visual Analogue Scale (0 = worst health and 100 = best health)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI responder criteria</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
    <description>Per the OMERACT-OARSI criteria, a subject is classified as a positive responder if at least one (1) of the following two (2) conditions is observed at the post-baseline assessment:&#xD;
In either pain (WOMAC pain subscale) or function (WOMAC function subscale), a high improvement in the subscale, where high improvement in a subscale is achieved if there is both a &gt; 50% improvement from Baseline and an absolute change from Baseline of &gt; 20 normalised units (0-100 scale) OR&#xD;
Improvement in at least two (2) of the following three (3):&#xD;
Improvement in pain (WOMAC pain subscale) defined as &gt; 20% improvement from Baseline and an absolute change from Baseline of &gt; 10 (0-100 scale)&#xD;
Improvement in function (WOMAC function subscale) defined as &gt; 20% improvement from Baseline and an absolute change from Baseline of &gt; 10 (0-100 scale)&#xD;
Improvement in PGA defined as &gt; 20% improvement from Baseline and an absolute change from Baseline of &gt; 10 mm (0-100 sc</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>PAAG-OA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synvisc-One</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-articular injection with Synvisc-One (hyaluronic acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAAG-OA</intervention_name>
    <description>Intra-articular injection of 6ml PAAG-OA in the target knee</description>
    <arm_group_label>PAAG-OA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synvisc-One</intervention_name>
    <description>Intra-articular injection of 6ml Synvisc-One in the target knee</description>
    <arm_group_label>Synvisc-One</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Male or female, aged ≥ 40 years&#xD;
&#xD;
          -  Clinical diagnosis of knee OA American College of Rheumatology criteria confirmed by&#xD;
             radiology&#xD;
&#xD;
          -  Definite radiographic OA in the most symptomatic knee (target knee) at mild to&#xD;
             moderate-stage (Kellgren-Lawrence grades 2 or 3)&#xD;
&#xD;
          -  Stable dose of analgesics for the past four weeks&#xD;
&#xD;
          -  NRS (11 points (0-10) pain intensity numerical rating scale) ≥ 4 in target knee,&#xD;
             during the past week when walking&#xD;
&#xD;
          -  Body Mass Index (BMI) between 20-35&#xD;
&#xD;
          -  For females of reproductive potential: use of adequate contraception must be used&#xD;
             throughout the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female participants who are pregnant, lactating or planning pregnancy during the&#xD;
             course of the clinical investigation&#xD;
&#xD;
          -  Contraindications to PAAG-OA or Synvisc-One®, according to IB or Instruction for Use&#xD;
             (IFU)&#xD;
&#xD;
          -  Previous intra-articular injection of polyacrylamide gel in the target knee&#xD;
&#xD;
          -  Previous intra-articular injection with hyaluronic acid or derivatives in target knee&#xD;
             in the previous 6 months&#xD;
&#xD;
          -  Significant valgus/varus deformity of the knee, ligamentous laxity or meniscal&#xD;
             instability&#xD;
&#xD;
          -  Other diseases in target knee than osteoarthritis&#xD;
&#xD;
          -  Intra-articular injection of any substance other than hyaluronic acid (e.g.&#xD;
             corticosteroids) in the target knee within the last 3 months&#xD;
&#xD;
          -  Acute serious infection of any region that required hospital care or intravenous&#xD;
             antibiotic treatment within the last 30 days, or oral antibiotic treatment within the&#xD;
             last 14 days&#xD;
&#xD;
          -  Skin disease or infections in the area of the injection site&#xD;
&#xD;
          -  Infected or severely inflamed knees&#xD;
&#xD;
          -  History of sepsis in any joint or any clinical concern for a subacute infectious&#xD;
             process in the target knee&#xD;
&#xD;
          -  History of surgery in the target knee within the past 6 months&#xD;
&#xD;
          -  Symptomatic osteoarthritis of the hips, spine or ankle, that interferes with the&#xD;
             evaluation of the target knee&#xD;
&#xD;
          -  Planned surgery on any lower extremity&#xD;
&#xD;
          -  Clinically significant venous or lymphatic stasis present in the legs&#xD;
&#xD;
          -  Clinically apparent tense effusion or inflammation in the target knee&#xD;
&#xD;
          -  Suffering from any unstable or severe cardio-vascular disease&#xD;
&#xD;
          -  Any contraindication to intra-articular e.g. anticoagulant therapy or clinical concern&#xD;
             for potential coagulopathy (e.g. liver disease)&#xD;
&#xD;
          -  Any foreign material in the target joint&#xD;
&#xD;
          -  Any significant medical condition (e.g. significant psychiatric or neurological&#xD;
             disorders or active alcohol/drug abuse), any medical condition that is unstable/poorly&#xD;
             controlled or other factors that may interfere with study participation&#xD;
&#xD;
          -  Treatment with systemic steroids&#xD;
&#xD;
          -  History of drug/alcohol abuse, mental dysfunction of other factors limiting their&#xD;
             ability to cooperate fully&#xD;
&#xD;
          -  Change in physiotherapy within the previous month&#xD;
&#xD;
          -  Fibromyalgia&#xD;
&#xD;
          -  Inflammatory or other disease/condition which may affect joints (e.g. rheumatoid&#xD;
             arthritis, psoriatic arthritis and ankylosing spondylitis among others)&#xD;
&#xD;
          -  Haemophilia&#xD;
&#xD;
          -  Any other condition that in the opinion of the investigator put a potential&#xD;
             participant at risk or otherwise precludes participation in the trial&#xD;
&#xD;
          -  Known allergic reactions to components of Synvisc-One (avian protein)&#xD;
&#xD;
          -  Known allergic reactions to antibiotics (azithromycin and moxifloxacin) or local&#xD;
             anaesthesia&#xD;
&#xD;
          -  Participation in any experimental device study within 6 months prior to enrolment, or&#xD;
             participation in an experimental drug study within 1 month prior to enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bliddal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Parker Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Parker Institute</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A2 Reumatologi og idrætsmedicin</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatolog i Odense</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

